inositol has been researched along with Body Weight in 137 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Myo-inositol supplementation may reduce insulin resistance (IR) with few serious side effects in patients with polycystic ovary syndrome (PCOS)." | 7.96 | Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model. ( Chen, X; Li, C; Zhang, W; Zhang, Y; Zheng, X, 2020) |
| "To evaluate the effects of the combination of d-chiro inositol and alpha lipoic acid on menstrual cycles and insulin sensitivity in women with polycystic ovary syndrome (PCOS)." | 7.91 | Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome. ( Canu, A; Capozzi, A; Fruzzetti, F; Lello, S, 2019) |
| "To investigate hormonal dynamics in a group of non-obese polycystic ovary syndrome (PCOS) patients under myo-inositol (MYO) administration." | 7.80 | Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. ( Campedelli, A; Chierchia, E; Despini, G; Genazzani, AD; Marini, G; Prati, A; Rattighieri, E; Ricchieri, F; Santagni, S; Simoncini, T, 2014) |
| "Brain myo-inositol, an organic osmolyte, is decreased in cirrhotic patients with hepatic encephalopathy but appears unchanged in fulminant hepatic failure." | 7.69 | Glutamine, myo-inositol, and organic brain osmolytes after portocaval anastomosis in the rat: implications for ammonia-induced brain edema. ( Blei, AT; Cordoba, J; Gottstein, J, 1996) |
| "The inositol compounds were administered via the drinking fluid." | 5.34 | Inhibition of chronic ulcerative colitis associated adenocarcinoma development in mice by inositol compounds. ( Liao, J; Lu, GG; Seril, DN; Yang, AL; Yang, GY, 2007) |
| "Myo-inositol supplementation at physiological doses during lactation improves metabolic health and prevents the programmed trend to develop insulin resistance and hypertriglyceridemia in male rats acquired by inadequate fetal nutrition and exacerbated by a diabetogenic diet in adulthood." | 4.02 | Sex-Specific Effects of Myo-Inositol Ingested During Lactation in the Improvement of Metabolic Health in Adult Rats. ( Castillo, P; Núñez, P; Otero, D; Palou, A; Palou, M; Picó, C, 2021) |
| "Myo-inositol supplementation may reduce insulin resistance (IR) with few serious side effects in patients with polycystic ovary syndrome (PCOS)." | 3.96 | Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model. ( Chen, X; Li, C; Zhang, W; Zhang, Y; Zheng, X, 2020) |
| "The aim of the study is to investigate the efficacy of a treatment with myoinositol plus L-tyrosine, selenium, and chromium in women with polycystic ovarian syndrome (PCOS)." | 3.91 | Efficacy of the synergic action of myoinositol, tyrosine, selenium and chromium in women with PCOS. ( Carra, MC; Lippa, A; Lisi, F; Montanino Oliva, M; Zuev, V, 2019) |
| "To evaluate the effects of the combination of d-chiro inositol and alpha lipoic acid on menstrual cycles and insulin sensitivity in women with polycystic ovary syndrome (PCOS)." | 3.91 | Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome. ( Canu, A; Capozzi, A; Fruzzetti, F; Lello, S, 2019) |
| " Body weight, blood glucose, glycated haemoglobin, insulin, serum leptin, HOMA-insulin resistance scores, intestinal amylase activity, serum and faecal lipids and food and fluid consumption were measured." | 3.83 | The effect of combined inositol hexakisphosphate and inositol supplement in streptozotocin-induced type 2 diabetic rats. ( Bustamante, J; Dilworth, LL; Foster, SR; Lindo, RL; Omoruyi, FO, 2016) |
| "To investigate hormonal dynamics in a group of non-obese polycystic ovary syndrome (PCOS) patients under myo-inositol (MYO) administration." | 3.80 | Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. ( Campedelli, A; Chierchia, E; Despini, G; Genazzani, AD; Marini, G; Prati, A; Rattighieri, E; Ricchieri, F; Santagni, S; Simoncini, T, 2014) |
| "Brain myo-inositol, an organic osmolyte, is decreased in cirrhotic patients with hepatic encephalopathy but appears unchanged in fulminant hepatic failure." | 3.69 | Glutamine, myo-inositol, and organic brain osmolytes after portocaval anastomosis in the rat: implications for ammonia-induced brain edema. ( Blei, AT; Cordoba, J; Gottstein, J, 1996) |
| " Furthermore, insulin but not myoinositol treatment normalized blood glucose and insulin levels, maintained normal prostate and body weight-gain, and prevented the decrease in the density, i." | 3.68 | Beta adrenergic receptor alterations in diabetic rat prostate: effects of insulin and dietary myoinositol. ( Gousse, A; Latifpour, J; Weiss, RM; Yoshida, M, 1991) |
| " Untreated alloxan diabetes reduced endoneurial sodium-gradient dependent uptake of the nonmetabolized amino acid 2-aminoisobutyric acid by greater than 50%." | 3.68 | A defect in sodium-dependent amino acid uptake in diabetic rabbit peripheral nerve. Correction by an aldose reductase inhibitor or myo-inositol administration. ( Carroll, PB; Fernstrom, JD; Finegold, DN; Greene, DA; Lattimer, SA, 1990) |
| " One group received no additional treatment whilst the other was given the aldose reductase inhibitor, sorbinil, by dietary admixture (approximate dose was 30 mg/day/kg body weight)." | 3.67 | Effects of sorbinil treatment in rats with chronic streptozotocin-diabetes; changes in lens and in substance P and catecholamines in the iris. ( Calcutt, NA; Clarke, HE; Compton, AM; Keen, P; Macdonald, IA; Tomlinson, DR; Willars, GB, 1989) |
| " Half of the diabetic rats were given the aldose reductase inhibitor, sorbinil (mean dose 30 mg/kg/day body weight by dietary admixture) over the entire protocol." | 3.67 | Substance P levels in peripheral nerve, skin, atrial myocardium and gastrointestinal tract of rats with long-term diabetes mellitus. Effects of aldose reductase inhibition. ( Calcutt, NA; Compton, AM; Keen, P; Tomlinson, DR; Willars, GB, 1989) |
| " Long-term treatment with linagliptin was well tolerated; adverse events (AEs) of special interest and serious AEs occurred in small percentages of patients." | 2.78 | Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes. ( Araki, E; Dugi, K; Hayashi, N; Horie, Y; Inagaki, N; Kawamori, R; Sarashina, A; Thiemann, S; von Eynatten, M; Watada, H; Woerle, HJ, 2013) |
| "An open-label prospective cross-over trial was performed to compare the efficacy and adverse effects of nateglinide with those of voglibose on Japanese early type 2 diabetes (who were oral hypoglycemic agent naïve and whose HbA(1C) levels were between 7." | 2.72 | Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study. ( Hirose, T; Kawamori, R; Kawasumi, M; Kurebayashi, S; Tanaka, Y; Watada, H, 2006) |
| "We tested whether long-term administration of voglibose (VO) prevents diet induced obesity in addition to hypoglycemic effects in high fat fed mice and further investigated the underlying mechanisms by which voglibose exerts its weight lowering effect." | 1.40 | Voglibose administration regulates body weight and energy intake in high fat-induced obese mice. ( Chung, JH; Do, HJ; Hwang, JW; Jin, T; Shin, MJ, 2014) |
| "The inositol compounds were administered via the drinking fluid." | 1.34 | Inhibition of chronic ulcerative colitis associated adenocarcinoma development in mice by inositol compounds. ( Liao, J; Lu, GG; Seril, DN; Yang, AL; Yang, GY, 2007) |
| " Increasing the bioavailability of arginine, the precursor of nitric oxide, thus potentially offers protection against end-stage disease." | 1.34 | Metabolic effects of a novel silicate inositol complex of the nitric oxide precursor arginine in the obese insulin-resistant JCR:LA-cp rat. ( Kelly, SE; Proctor, SD; Russell, JC; Vine, DF, 2007) |
| "Dietary myo-inositol is an effective inhibitor of lung tumor induction in mice, but no dose-response studies have been reported." | 1.31 | Dose-response study of myo-inositol as an inhibitor of lung tumorigenesis induced in A/J mice by benzo. ( Hecht, SS; Kenney, PM; Upadhyaya, P; Wang, M, 2001) |
| "After 6 weeks of untreated streptozotocin diabetes, rats were treated for 2 weeks." | 1.30 | Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. ( Basso, M; Cameron, NE; Cotter, MA; Hohman, TC, 1997) |
| "At 8 months galactosemia reduced NCV to 58% of control values, while ARI-treatment for 8 months improved NCV to 71% of control values." | 1.29 | Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy. ( Basso, M; Cherian, PV; Hohman, TC; Kamijo, M; Sima, AA, 1994) |
| "Primaquine treatment did not affect diabetic rats." | 1.29 | Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. ( Archibald, V; Cameron, NE; Cotter, MA; Dines, KC; Maxfield, EK, 1994) |
| "Methylguanidine was only approximately 7% as effective as aminoguanidine as an inhibitor of AGE formation from L-lysine and G6P; both compounds were poor inhibitors of AR." | 1.29 | Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. ( Chang, K; Corbett, JA; Currie, MG; Hasan, KS; McDaniel, ML; Misko, TP; Moore, WM; Petrash, JM; Smith, SR; Tilton, RG, 1993) |
| "Inositol is a major component of the intracellular mediators of insulin action." | 1.28 | Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. ( Bogardus, C; Craig, J; Hansen, BC; Hill, CR; Kennington, AS; Larner, J; Ortmeyer, HK; Raz, I; Romero, G, 1990) |
| "Iloprost was administered intraperitoneally to streptozotocin-induced diabetic rats at a dose of 10 micrograms/kg/day for a month." | 1.28 | Effect of a prostaglandin I2 derivative (iloprost) on peripheral neuropathy of diabetic rats. ( Ito, H; Kanazawa, A; Miwa, T; Ohno, A; Tanaka, A, 1992) |
| "Myo-inositol concentration was decreased in liver, heart and kidney but not in brain, pancreas and skeletal muscle." | 1.28 | Effect of short- and long-term diabetes on carnitine and myo-inositol in rats. ( Baker, H; DeAngelis, B; Frank, O; Jyothirmayi, GN; Reddi, AS, 1991) |
| " Body weight data did not suggest any overt toxic effect of long-term administration of InsP6, Ins or InsP6 + Ins." | 1.28 | Inositol and inositol hexaphosphate suppress cell proliferation and tumor formation in CD-1 mice. ( Chakravarthy, AK; Shamsuddin, AM; Ullah, A, 1989) |
| "Sorbinil treatment prevented the 10-fold increase in nerve sorbitol found with diabetes." | 1.27 | The effects of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat. ( Cameron, NE; Leonard, MB; Ross, IS; Whiting, PH, 1986) |
| "A more mild degree of galactosemia, induced by 5 or 21 days of feeding a diet containing 10% galactose to nondiabetic rats, provoked an increase in nerve water content associated with polyol levels of a similar order to those seen in diabetes." | 1.27 | Does galactose feeding provide a valid model of consequences of exaggerated polyol-pathway flux in peripheral nerve in experimental diabetes? ( Lambourne, JE; Tomlinson, DR; Willars, GB, 1987) |
| " Hence, it is suggested that the impact of dietary phytate on trace mineral bioavailability will depend upon the presence of factors, including excess calcium, that alter the absorption and utilization of phytate." | 1.26 | Metabolism of 14C-phytate in rats: effect of low and high dietary calcium intakes. ( Nahapetian, A; Young, VR, 1980) |
| "The results show that marginal protein deficiency does not alter either the biosynthesis of inositol or inositol concentration in the testis, epididymis or seminal vesicles." | 1.25 | Effect of dietary protein on the biosynthesis of inositol in rat testes. ( , 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 55 (40.15) | 18.7374 |
| 1990's | 34 (24.82) | 18.2507 |
| 2000's | 22 (16.06) | 29.6817 |
| 2010's | 19 (13.87) | 24.3611 |
| 2020's | 7 (5.11) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, Q | 1 |
| Zhang, Y | 2 |
| Li, L | 3 |
| Li, J | 1 |
| Li, Y | 1 |
| Han, L | 1 |
| Wang, M | 2 |
| Montanino Oliva, M | 1 |
| Zuev, V | 1 |
| Lippa, A | 1 |
| Carra, MC | 1 |
| Lisi, F | 1 |
| Li, C | 1 |
| Zhang, W | 1 |
| Zheng, X | 1 |
| Chen, X | 1 |
| Liu, X | 1 |
| Li, SP | 1 |
| Rackayová, V | 1 |
| Flatt, E | 1 |
| Braissant, O | 1 |
| Grosse, J | 1 |
| Capobianco, D | 1 |
| Mastromarino, P | 1 |
| McMillin, M | 1 |
| DeMorrow, S | 1 |
| McLin, VA | 1 |
| Cudalbu, C | 1 |
| Guimarães, VHD | 1 |
| Basilio Silva, JN | 1 |
| de Freitas, DF | 1 |
| Filho, OC | 1 |
| da Silveira, LH | 1 |
| Marinho, BM | 1 |
| de Paula, AMB | 1 |
| Melo, GA | 1 |
| Santos, SHS | 1 |
| Castillo, P | 1 |
| Palou, M | 1 |
| Otero, D | 1 |
| Núñez, P | 1 |
| Palou, A | 1 |
| Picó, C | 1 |
| Ge, LQ | 2 |
| Huang, B | 1 |
| Jiang, YP | 2 |
| Gu, HT | 1 |
| Xia, T | 2 |
| Yang, GQ | 1 |
| Liu, F | 1 |
| Wu, JC | 2 |
| Stracquadanio, M | 1 |
| Ciotta, L | 1 |
| Palumbo, MA | 1 |
| Gazdzinski, SP | 1 |
| Gaździńska, AP | 1 |
| Orzeł, J | 1 |
| Redlisz-Redlicki, G | 1 |
| Pietruszka, M | 1 |
| Mojkowska, A | 1 |
| Pacho, RA | 1 |
| Wylezol, M | 1 |
| Bevilacqua, A | 1 |
| Dragotto, J | 1 |
| Giuliani, A | 1 |
| Bizzarri, M | 1 |
| Fruzzetti, F | 1 |
| Capozzi, A | 1 |
| Canu, A | 1 |
| Lello, S | 1 |
| Dai, B | 1 |
| Huang, S | 1 |
| Deng, Y | 1 |
| Januszewski, M | 1 |
| Issat, T | 1 |
| Jakimiuk, AA | 1 |
| Santor-Zaczynska, M | 1 |
| Jakimiuk, AJ | 1 |
| Advani, K | 1 |
| Batra, M | 1 |
| Tajpuriya, S | 1 |
| Gupta, R | 1 |
| Saraswat, A | 1 |
| Nagar, HD | 1 |
| Makwana, L | 1 |
| Kshirsagar, S | 1 |
| Kaul, P | 1 |
| Ghosh, AK | 1 |
| Pradhan, S | 1 |
| Mehta, A | 1 |
| Jaiswal, A | 1 |
| Nakhate, KT | 1 |
| Kamdi, S | 1 |
| Do, HJ | 2 |
| Jin, T | 1 |
| Chung, JH | 1 |
| Hwang, JW | 1 |
| Shin, MJ | 2 |
| Lee, DW | 1 |
| Nam, YK | 1 |
| Kim, TK | 1 |
| Kim, JH | 1 |
| Kim, SY | 1 |
| Min, JW | 1 |
| Lee, JH | 1 |
| Kim, HY | 1 |
| Kim, DJ | 1 |
| Choe, BY | 1 |
| Genazzani, AD | 2 |
| Santagni, S | 1 |
| Ricchieri, F | 2 |
| Campedelli, A | 1 |
| Rattighieri, E | 1 |
| Chierchia, E | 1 |
| Marini, G | 1 |
| Despini, G | 1 |
| Prati, A | 1 |
| Simoncini, T | 1 |
| Li, XW | 1 |
| Hao, W | 1 |
| Liu, Y | 1 |
| Yang, JR | 1 |
| Jiang, Y | 1 |
| Liu, Z | 1 |
| You, L | 1 |
| Wu, Y | 2 |
| Xu, B | 2 |
| Ge, L | 1 |
| Stanley, D | 1 |
| Song, Q | 1 |
| Wu, J | 1 |
| Liu, ZY | 1 |
| You, LL | 1 |
| Song, QS | 1 |
| Lee, YS | 1 |
| Ha, MJ | 1 |
| Cho, Y | 1 |
| Yi, H | 1 |
| Hwang, YJ | 1 |
| Hwang, GS | 1 |
| Foster, SR | 1 |
| Omoruyi, FO | 1 |
| Bustamante, J | 1 |
| Lindo, RL | 1 |
| Dilworth, LL | 1 |
| Antony, PJ | 1 |
| Gandhi, GR | 1 |
| Stalin, A | 1 |
| Balakrishna, K | 1 |
| Toppo, E | 1 |
| Sivasankaran, K | 1 |
| Ignacimuthu, S | 1 |
| Al-Dhabi, NA | 1 |
| Choi, MS | 1 |
| Lee, MK | 1 |
| Jung, UJ | 1 |
| Kim, HJ | 1 |
| Do, GM | 1 |
| Park, YB | 1 |
| Jeon, SM | 1 |
| Sivakumar, S | 1 |
| Subramanian, SP | 1 |
| Seino, Y | 2 |
| Fujita, T | 1 |
| Hiroi, S | 1 |
| Hirayama, M | 1 |
| Kaku, K | 1 |
| Araki, E | 1 |
| Kawamori, R | 2 |
| Inagaki, N | 1 |
| Watada, H | 2 |
| Hayashi, N | 1 |
| Horie, Y | 1 |
| Sarashina, A | 1 |
| Thiemann, S | 1 |
| von Eynatten, M | 1 |
| Dugi, K | 1 |
| Woerle, HJ | 1 |
| Yasuda, K | 2 |
| Shimowada, K | 1 |
| Uno, M | 1 |
| Odaka, H | 2 |
| Adachi, T | 1 |
| Shihara, N | 1 |
| Suzuki, N | 1 |
| Tamon, A | 1 |
| Nagashima, K | 1 |
| Hosokawa, M | 1 |
| Tsuda, K | 1 |
| Ott, EA | 1 |
| Smith, WH | 1 |
| Stob, M | 1 |
| Beeson, WM | 1 |
| VINCENDEAU, J | 1 |
| WOOD, JD | 1 |
| YAGI, K | 4 |
| KOTAKI, A | 3 |
| YAMAMOTO, Y | 2 |
| Isoda, F | 1 |
| Shiry, L | 1 |
| Abergel, J | 1 |
| Allan, G | 1 |
| Mobbs, C | 1 |
| Witschi, H | 2 |
| Espiritu, I | 2 |
| Ly, M | 1 |
| Uyeminami, D | 2 |
| Rai, A | 1 |
| Reddy, HR | 1 |
| Schmidt, RE | 1 |
| Dorsey, DA | 1 |
| Beaudet, LN | 1 |
| Parvin, CA | 1 |
| Yarasheski, KE | 1 |
| Smith, SR | 2 |
| Williamson, JR | 1 |
| Peterson, RG | 1 |
| Oates, PJ | 1 |
| Liao, Y | 1 |
| Takashima, S | 1 |
| Zhao, H | 1 |
| Asano, Y | 1 |
| Shintani, Y | 1 |
| Minamino, T | 1 |
| Kim, J | 2 |
| Fujita, M | 1 |
| Hori, M | 1 |
| Kitakaze, M | 1 |
| Kurebayashi, S | 1 |
| Tanaka, Y | 1 |
| Kawasumi, M | 1 |
| Hirose, T | 1 |
| Lam, S | 1 |
| McWilliams, A | 1 |
| LeRiche, J | 1 |
| MacAulay, C | 1 |
| Wattenberg, L | 1 |
| Szabo, E | 1 |
| Liao, J | 1 |
| Seril, DN | 1 |
| Yang, AL | 1 |
| Lu, GG | 1 |
| Yang, GY | 1 |
| Castro-Fornieles, J | 1 |
| Bargalló, N | 1 |
| Lázaro, L | 1 |
| Andrés, S | 1 |
| Falcon, C | 1 |
| Plana, MT | 1 |
| Junqué, C | 1 |
| Wang, Q | 1 |
| Cryns, K | 1 |
| Shamir, A | 1 |
| Van Acker, N | 1 |
| Levi, I | 1 |
| Daneels, G | 1 |
| Goris, I | 1 |
| Bouwknecht, JA | 1 |
| Andries, L | 1 |
| Kass, S | 1 |
| Agam, G | 2 |
| Belmaker, H | 1 |
| Bersudsky, Y | 1 |
| Steckler, T | 1 |
| Moechars, D | 1 |
| Proctor, SD | 1 |
| Kelly, SE | 1 |
| Vine, DF | 1 |
| Russell, JC | 1 |
| Lanzoni, C | 1 |
| Jasonni, VM | 1 |
| Greene, DA | 7 |
| Yagihashi, S | 3 |
| Lattimer, SA | 4 |
| Sima, AA | 3 |
| Ford, WC | 1 |
| Hamilton, DW | 1 |
| Clements, RS | 1 |
| Stockard, CR | 1 |
| Nahapetian, A | 1 |
| Young, VR | 1 |
| Gillon, KR | 1 |
| Hawthorne, JN | 1 |
| Andersen, DB | 3 |
| Holub, BJ | 3 |
| Cohen, AM | 1 |
| Wald, H | 1 |
| Popovtzer, M | 1 |
| Rosenmann, E | 1 |
| Hotta, N | 2 |
| Kakuta, H | 2 |
| Fukasawa, H | 2 |
| Koh, N | 2 |
| Sakakibara, F | 2 |
| Nakamura, J | 2 |
| Hamada, Y | 2 |
| Wakao, T | 1 |
| Hara, T | 2 |
| Mori, K | 1 |
| Tyan, ML | 1 |
| Tilton, RG | 1 |
| Chang, K | 1 |
| Hasan, KS | 1 |
| Petrash, JM | 1 |
| Misko, TP | 1 |
| Moore, WM | 1 |
| Currie, MG | 1 |
| Corbett, JA | 1 |
| McDaniel, ML | 1 |
| Kenney, JL | 1 |
| Carlberg, KA | 1 |
| Kamijo, M | 2 |
| Basso, M | 2 |
| Cherian, PV | 1 |
| Hohman, TC | 3 |
| Cameron, NE | 4 |
| Cotter, MA | 3 |
| Archibald, V | 1 |
| Dines, KC | 1 |
| Maxfield, EK | 1 |
| Pohjanvirta, R | 1 |
| Hirvonen, MR | 1 |
| Unkila, M | 1 |
| Savolainen, K | 1 |
| Tuomisto, J | 1 |
| Stevens, MJ | 2 |
| Van Huysen, C | 2 |
| Williams, CM | 1 |
| Maunder, K | 1 |
| Terril-Robb, LA | 1 |
| Clemons, DJ | 1 |
| Besch-Williford, C | 1 |
| O'Brien, DP | 1 |
| O'Dell, BL | 1 |
| Cordoba, J | 1 |
| Gottstein, J | 1 |
| Blei, AT | 1 |
| Sakamoto, N | 1 |
| Lauden, A | 1 |
| Kofman, O | 1 |
| Sobolev, Y | 1 |
| Setchell, BP | 2 |
| Plöen, L | 1 |
| Ritzen, EM | 1 |
| Koyama, M | 1 |
| Wada, R | 1 |
| Mizukami, H | 1 |
| Sakuraba, H | 1 |
| Ikeda, H | 1 |
| Obrosova, IG | 1 |
| Fathallah, L | 1 |
| Cao, X | 1 |
| Kato, N | 2 |
| Mizuno, K | 2 |
| Makino, M | 1 |
| Suzuki, T | 1 |
| Hecht, SS | 1 |
| Kenney, PM | 1 |
| Upadhyaya, P | 1 |
| Coppey, LJ | 1 |
| Gellett, JS | 1 |
| Davidson, EP | 1 |
| Dunlap, JA | 1 |
| Lund, DD | 1 |
| Salvemini, D | 1 |
| Yorek, MA | 1 |
| Takami, K | 1 |
| Takeda, N | 1 |
| Nakashima, K | 1 |
| Takami, R | 1 |
| Hayashi, M | 1 |
| Ozeki, S | 1 |
| Yamada, A | 1 |
| Kokubo, Y | 1 |
| Sato, M | 1 |
| Kawachi, S | 1 |
| Sasaki, A | 1 |
| French, FA | 1 |
| Burton, LE | 2 |
| Ray, RE | 1 |
| Bradford, JR | 1 |
| Orr, JP | 1 |
| Nickerson, JA | 1 |
| Wells, WW | 2 |
| Fischer, M | 1 |
| Falkensammer, C | 1 |
| Maurice, DV | 1 |
| Jensen, LS | 2 |
| Ohno, A | 1 |
| Kanazawa, A | 1 |
| Tanaka, A | 1 |
| Miwa, T | 1 |
| Ito, H | 1 |
| Whiteside, CI | 1 |
| Thompson, JC | 1 |
| Matsubara, A | 1 |
| Nakano, K | 1 |
| Kurono, M | 1 |
| Reddi, AS | 2 |
| Jyothirmayi, GN | 2 |
| Leevy, CB | 1 |
| Khalil, M | 1 |
| DeAngelis, B | 2 |
| Frank, O | 2 |
| Baker, H | 2 |
| Schmolke, M | 1 |
| Schleicher, E | 1 |
| Guder, WG | 1 |
| Sonobe, M | 2 |
| Yasuda, H | 2 |
| Hisanaga, T | 1 |
| Maeda, K | 1 |
| Yamashita, M | 2 |
| Kawabata, T | 1 |
| Kikkawa, R | 2 |
| Taniguchi, Y | 1 |
| Shigeta, Y | 2 |
| Rushovich, EH | 1 |
| Thomas, TP | 1 |
| Ueda, T | 1 |
| Agranoff, BW | 1 |
| Gousse, A | 1 |
| Yoshida, M | 1 |
| Weiss, RM | 1 |
| Latifpour, J | 1 |
| Willars, GB | 5 |
| Calcutt, NA | 3 |
| Tomlinson, DR | 6 |
| Akashi, M | 1 |
| Akazawa, S | 1 |
| Akazawa, M | 1 |
| Trocino, R | 1 |
| Hashimoto, M | 1 |
| Maeda, Y | 1 |
| Yamamoto, H | 1 |
| Kawasaki, E | 1 |
| Takino, H | 1 |
| Yokota, A | 1 |
| Sredy, J | 1 |
| Flam, BR | 1 |
| Sawicki, DR | 1 |
| Llewelyn, JG | 1 |
| Thomas, PK | 1 |
| Mirrlees, DJ | 1 |
| Suzuki, K | 1 |
| Yen-Chung, H | 1 |
| Toyota, T | 1 |
| Goto, Y | 1 |
| Hirata, Y | 1 |
| Okada, K | 1 |
| Carroll, PB | 1 |
| Fernstrom, JD | 1 |
| Finegold, DN | 1 |
| Kennington, AS | 1 |
| Hill, CR | 1 |
| Craig, J | 1 |
| Bogardus, C | 1 |
| Raz, I | 1 |
| Ortmeyer, HK | 1 |
| Hansen, BC | 1 |
| Romero, G | 1 |
| Larner, J | 1 |
| Mayer, JH | 1 |
| Townsend, J | 1 |
| Compton, AM | 3 |
| Churchill, RD | 1 |
| Macdonald, IA | 1 |
| Clarke, HE | 1 |
| Keen, P | 2 |
| Legan, E | 1 |
| Shamsuddin, AM | 1 |
| Ullah, A | 1 |
| Chakravarthy, AK | 1 |
| Leclerc, J | 1 |
| Miller, ML | 1 |
| Egberts, J | 1 |
| Gorree, GC | 1 |
| Reyngoud, DJ | 1 |
| Mackway, AM | 1 |
| Leonard, MB | 1 |
| Ross, IS | 1 |
| Whiting, PH | 1 |
| Kemper, C | 1 |
| Dvornik, D | 1 |
| Datta, SC | 1 |
| Radin, NS | 1 |
| Anceschi, MM | 1 |
| Petrelli, A | 1 |
| Zaccardo, G | 1 |
| Barbati, A | 1 |
| Di Renzo, GC | 1 |
| Cosmi, EV | 1 |
| Hallman, M | 1 |
| Hatanaka, I | 1 |
| Terada, M | 1 |
| Sussman, I | 1 |
| Matschinsky, FM | 1 |
| Lambourne, JE | 1 |
| Laird, RD | 1 |
| Drill, VA | 1 |
| Smith, GS | 1 |
| Chambers, JW | 1 |
| Neumann, AL | 1 |
| Ray, EE | 1 |
| Nelson, AB | 1 |
| Hegsted, DM | 1 |
| Gallagher, A | 1 |
| Hanford, H | 1 |
| Schumaier, GW | 1 |
| Funk, AD | 1 |
| Smith, TC | 1 |
| Falen, L | 1 |
| Jaeger, JJ | 1 |
| McGrath, JJ | 1 |
| Nelson, TS | 1 |
| Shieh, TR | 1 |
| Wodzinski, RJ | 1 |
| Ware, JH | 1 |
| Ronaghy, HA | 1 |
| Reinhold, JG | 1 |
| Mahloudji, M | 1 |
| Ghavami, P | 1 |
| Fox, MR | 1 |
| Halsted, JA | 1 |
| Ghittoni, NE | 1 |
| Faryna de Raveglia, I | 1 |
| Pearce, J | 1 |
| Wolford, JH | 1 |
| Murphy, D | 1 |
| Andrews, JW | 1 |
| Murai, T | 1 |
| Campbell, C | 1 |
| Cook, RM | 1 |
| Kubena, LF | 1 |
| Deaton, JW | 1 |
| Chen, TC | 1 |
| Reece, FN | 1 |
| Hasan, SH | 2 |
| Nishigaki, I | 1 |
| Tsutsui, Y | 1 |
| Waites, GM | 1 |
| Schryver, HF | 1 |
| Hintz, HF | 1 |
| Craig, PH | 1 |
| Leveille, GA | 1 |
| Bray, DJ | 1 |
| Linari, G | 1 |
| Natsume, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan[NCT01263483] | Phase 2/Phase 3 | 230 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Long-term, Open-label Extension Study to Investigate the Long-term Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan[NCT01263509] | Phase 2/Phase 3 | 179 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Effects of a Supplementation With Zinc and Myo-inositol in Paediatric Obesity[NCT03283813] | Phase 4 | 60 participants (Anticipated) | Interventional | 2018-02-05 | Recruiting | ||
| Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups[NCT00328601] | Phase 3 | 170 participants | Interventional | 2005-02-28 | Completed | ||
| A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury[NCT01548690] | Phase 2 | 47 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Immunohistochemical Analysis of Human Transbronchial Biopsy Specimens Collected in a Phase I Chemoprevention Trial of Myo-Inositol in Heavy Smokers Conducted Outside the Intramural NCI Program[NCT00342836] | Phase 1 | 20 participants | Interventional | 2005-04-30 | Completed | ||
| Zinc, Iron and Vitamin A Supplementation for Infant Growth and Development, and the Contributing Role of Psychosocial Care[NCT02319499] | Phase 3 | 800 participants (Actual) | Interventional | 1998-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | mg/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 72.4 |
| Alogliptin 12.5 mg QD | 40.9 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 38.7 |
The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | mg·hr/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -4.3 |
| Alogliptin 12.5 mg QD | -74.7 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -76.8 |
The change between the value of C-peptide collected at week 12 or final visit and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | ng·hr/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.14 |
| Alogliptin 12.5 mg QD | 0.69 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.57 |
The change between the value of fasting C-peptide collected at week 12 or final visit and fasting C-peptide collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | ng/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.02 |
| Alogliptin 12.5 mg QD | 0.06 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.10 |
The change between the value of fasting C-peptide collected at week 2 and fasting C-peptide collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 2.
| Intervention | ng/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.03 |
| Alogliptin 12.5 mg QD | -0.07 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.01 |
The change between the value of fasting C-peptide collected at week 4 and fasting C-peptide collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 4.
| Intervention | ng/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.05 |
| Alogliptin 12.5 mg QD | 0.06 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.01 |
The change between the value of fasting C-peptide collected at week 8 and fasting C-peptide collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 8.
| Intervention | ng/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.07 |
| Alogliptin 12.5 mg QD | 0.03 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.01 |
The change between the value of fasting plasma glucose collected at week 12 or final visit and fasting plasma glucose collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | mg/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -5.6 |
| Alogliptin 12.5 mg QD | -19.1 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -18.5 |
The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 2
| Intervention | mg/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -3.5 |
| Alogliptin 12.5 mg QD | -15.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -18.8 |
The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 4.
| Intervention | mg/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -0.6 |
| Alogliptin 12.5 mg QD | -16.2 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -22.6 |
The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 8.
| Intervention | mg/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -2.5 |
| Alogliptin 12.5 mg QD | -20.8 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -21.9 |
The change between the value of glucagons collected at week 12 or final visit and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12
| Intervention | pg·hr/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -0.4 |
| Alogliptin 12.5 mg QD | -19.2 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -20.5 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.04 |
| Alogliptin 12.5 mg QD | -0.96 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.91 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 2.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -0.01 |
| Alogliptin 12.5 mg QD | -0.19 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.21 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 4.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -0.02 |
| Alogliptin 12.5 mg QD | -0.44 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.43 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 8.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -0.01 |
| Alogliptin 12.5 mg QD | -0.74 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.75 |
The change between the value of insulin collected at week 12 or final visit and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12
| Intervention | μU·hr/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -2.47 |
| Alogliptin 12.5 mg QD | 4.62 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 1.50 |
The change between the value of blood glucose collected at week 52 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 39.6 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 39.4 |
The change between the value of blood glucose collected at week 12 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 41.2 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 37.6 |
The change between the value of blood glucose collected at week 24 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 38.0 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 37.1 |
The change between the value of blood glucose collected at week 52 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 39.0 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 40.8 |
The change between the value of blood glucose collected at week 52 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | mg•hr/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -77.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -82.2 |
The change between the value of blood glucose collected at week 12 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | mg•hr/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -73.2 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -76.8 |
The change between the value of blood glucose collected at week 24 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | mg•hr/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -69.0 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -70.4 |
The change between the value of blood glucose collected at week 52 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | mg•hr/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -83.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -83.4 |
The change between the value of C-peptide collected at week 52 or final visit and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | ng•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 1.05 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.80 |
The change between the value of C-peptide collected at week 12 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | ng•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.71 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.71 |
The change between the value of C-peptide collected at week 24 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | ng•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 1.38 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 1.12 |
The change between the value of C-peptide collected at week 52 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | ng•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.96 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 2.18 |
The change between the value of fasting C-peptide collected at week 52 or final visit and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.31 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.29 |
The change between the value of fasting C-peptide collected at week 12 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.10 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.13 |
The change between the value of fasting C-peptide collected at week 16 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 16.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.24 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.21 |
The change between the value of fasting C-peptide collected at week 20 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 20.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.24 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.15 |
The change between the value of fasting C-peptide collected at week 24 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.19 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.14 |
The change between the value of fasting C-peptide collected at week 28 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 28.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.18 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.25 |
The change between the value of fasting C-peptide collected at week 32 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 32.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.47 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.31 |
The change between the value of fasting C-peptide collected at week 36 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 36.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.33 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.38 |
The change between the value of fasting C-peptide collected at week 40 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 40.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.30 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.37 |
The change between the value of fasting C-peptide collected at week 44 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 44.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.08 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.25 |
The change between the value of fasting C-peptide collected at week 48 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 48.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.45 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.38 |
The change between the value of fasting C-peptide collected at week 52 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.80 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.40 |
The change between the value of fasting C-peptide collected at week 8 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 8.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.05 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.11 |
The change between the value of fasting plasma glucose collected at week 52 or final visit and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -17.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -23.3 |
The change between the value of fasting plasma glucose collected at week 12 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -17.1 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -18.8 |
The change between the value of fasting plasma glucose collected at week 16 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 16.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -16.0 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -15.3 |
The change between the value of fasting plasma glucose collected at week 20 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 20.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -15.6 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -15.0 |
The change between the value of fasting plasma glucose collected at week 24 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -13.8 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -15.6 |
The change between the value of fasting plasma glucose collected at week 28 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 28.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -14.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -21.9 |
The change between the value of fasting plasma glucose collected at week 32 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 32.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -17.7 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -20.1 |
The change between the value of fasting plasma glucose collected at week 36 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 36.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -17.3 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -22.6 |
The change between the value of fasting plasma glucose collected at week 40 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 40.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -19.7 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -22.8 |
The change between the value of fasting plasma glucose collected at week 44 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 44.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -21.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -24.4 |
The change between the value of fasting plasma glucose collected at week 48 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 48.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -20.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -23.1 |
The change between the value of fasting plasma glucose collected at week 52 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -20.7 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -24.0 |
The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 8.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -18.2 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -20.4 |
The change between the value of glucagons collected at week 52 or final visit and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | pg•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -11.7 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -20.9 |
The change between the value of glucagons collected at week 12 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | pg•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -14.3 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -20.0 |
The change between the value of glucagons collected at week 24 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | pg•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -4.6 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -6.8 |
The change between the value of glucagons collected at week 52 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | pg•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -12.0 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -22.2 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 or final visit and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.81 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.89 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.89 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.96 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 16.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.91 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.96 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 20.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.90 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.89 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.83 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.88 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 28 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 28.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.81 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.89 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 32 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 32.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.80 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.85 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 36 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 36.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.82 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.90 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 40 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 40.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.78 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.92 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 44 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 44.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.88 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.94 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 48 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 48.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.92 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.94 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.95 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.95 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 8.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.69 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.79 |
The change between the value of insulin collected at week 52 or final visit and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | μU•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.61 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.01 |
The change between the value of insulin collected at week 12 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | μU•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 3.05 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 2.95 |
The change between the value of insulin collected at week 24 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | μU•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 4.42 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 2.26 |
The change between the value of insulin collected at week 52 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | μU•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -1.28 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.18 |
A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug, which increases in intensity after the start of dosing. Adverse events data with onset occurring more than 30 days after last dose of study drug (AE start date - last dose date >30) will be listed, but not included in the summary tables below. (NCT01263509)
Timeframe: 52 Weeks.
| Intervention | participants (Number) | ||
|---|---|---|---|
| Serious Adverse Event | Serious Adverse Event Related to Study Drug | Other Adverse Events (Incidence ≥3%) | |
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 6 | 0 | 85 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 7 | 1 | 73 |
To evaluate the effect of OCR-002 on ammonia levels in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: Baseline and 72 Hours
| Intervention | Percent Change (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 41.2 |
| Maximum Dose Level 6.65 g/24h | 16.6 |
| Maximum Dose Level 10 g/24h | 41.8 |
| Maximum Dose Level 20g/24h | 38.4 |
To evaluate the steady state pharmacokinetic and pharmacodynamic profile of OCR-002 in patients with impaired and intact renal function using urinary phenylacetylglutamine (PAGN) as a surrogate marker (NCT01548690)
Timeframe: 24 Hours after last infusion
| Intervention | micrograms per millileter (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 65.6 |
| Maximum Dose Level 6.65 g/24h | 32.2 |
| Maximum Dose Level 10 g/24h | 33.4 |
| Maximum Dose Level 20g/24h | 104.9 |
The orientation log focuses on orientation to place, time, and circumstance. There are 10 items on the orientation log, which are scored 0-3. A spontaneous correct response is awarded 3 points. A spontaneous response that is lacking or incorrect, but a correct response is provided following a logical cue is awarded 2 points. A score of 1 is given if spontaneous and cued responses are lacking or incorrect, but a correct response is provided in a recognition format. A score of 0 is given if the spontaneous, cued, or recognition format does not generate a correct answer. Scores from the 10 items are summed and the final score ranges from 0 to 30. (NCT01548690)
Timeframe: 30 Days
| Intervention | units on a scale (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 23.8 |
| Maximum Dose Level 6.65 g/24h | 24.0 |
| Maximum Dose Level 10 g/24h | 24.0 |
| Maximum Dose Level 20g/24h | 24.0 |
The West Haven Criteria (WHC) for Hepatic Encephalopathy measures the severity of encephalopathy and patient's level of consciousness. The scale ranges from 0 to 4; a minimum score of 0 represents a better outcome, and a maximum total score of 4 represents a worse outcome. A score of 0 corresponds to normal consciousness and behavior and normal neurological examination. A score of 1 corresponds to mild lack of awareness, shortened attention span, and impaired addition or subtraction; mild asterixis or tremor. A score of 2 corresponds to lethargy, disorientated or inappropriate behavior, obvious asterixis; slurred speech. A score of 3 corresponds to somnolent but arousable, gross disorientation or bizarre behavior, muscle rigidity and clonus; hyperreflexia. A score of 4 corresponds to coma and decerebrate posturing. (NCT01548690)
Timeframe: 120 hours from start of infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 2.4 |
| Maximum Dose Level 6.65 g/24h | 3.2 |
| Maximum Dose Level 10 g/24h | 1.6 |
| Maximum Dose Level 20g/24h | 1.8 |
To evaluate the safety and tolerability of OCR-002 in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 0 |
| Maximum Dose Level 6.65 g/24h | 0 |
| Maximum Dose Level 10 g/24h | 0 |
| Maximum Dose Level 20g/24h | 0 |
8 trials available for inositol and Body Weight
| Article | Year |
|---|---|
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibito | 2011 |
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibito | 2011 |
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibito | 2011 |
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibito | 2011 |
Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Blood Glucose; Body Mass Index; Body Weight; Diabetes | 2013 |
Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study.
Topics: Aged; alpha-Glucosidases; Appetite; Body Weight; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus | 2006 |
A phase I study of myo-inositol for lung cancer chemoprevention.
Topics: Adult; Aged; Blood Pressure; Body Weight; Chemoprevention; Dose-Response Relationship, Drug; Female; | 2006 |
Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome.
Topics: Blood Glucose; Body Mass Index; Body Weight; Estradiol; Female; Folic Acid; Follicle Stimulating Hor | 2008 |
Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes.
Topics: Abdomen; Adipose Tissue; Adult; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Cholestero | 2002 |
[New drug combination for medical management of hyperlipemia: clinical study].
Topics: Aged; Blood Glucose; Body Weight; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; | 1977 |
Zinc supplementation of malnourished schoolboys in Iran: increased growth and other effects.
Topics: Adolescent; Blood Proteins; Body Height; Body Weight; Bone Development; Bread; Carbonates; Clinical | 1974 |
129 other studies available for inositol and Body Weight
| Article | Year |
|---|---|
D-
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Body Weight; Diet, High-Fat; Fatty Liver; Gluco | 2022 |
Efficacy of the synergic action of myoinositol, tyrosine, selenium and chromium in women with PCOS.
Topics: Body Weight; Chromium; Dose-Response Relationship, Drug; Female; Humans; Inositol; Polycystic Ovary | 2019 |
Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model.
Topics: Animals; Blood Glucose; Body Weight; Estrous Cycle; Female; Follicle Stimulating Hormone; Gene Expre | 2020 |
Letter to "May myo-inositol and D-chiro-inositol (40:1) treatment be a good option on normal-weighted polycystic ovary syndrome patients without insulin resistance?"
Topics: Body Weight; Female; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndrome | 2021 |
Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease.
Topics: Ammonium Compounds; Animals; Behavior, Animal; Bifidobacterium; Bile Ducts; Bilirubin; Blood Glucose | 2021 |
Hydroalcoholic Extract of Solanum lycocarpum A. St. Hil. (Solanaceae) Leaves Improves Alloxan-Induced Diabetes Complications in Mice.
Topics: Alanine Transaminase; Alkaline Phosphatase; Alloxan; alpha-Tocopherol; Animals; Aspartate Aminotrans | 2021 |
Sex-Specific Effects of Myo-Inositol Ingested During Lactation in the Improvement of Metabolic Health in Adult Rats.
Topics: Adipose Tissue, White; Animals; Body Weight; Caloric Restriction; Dietary Supplements; Eating; Energ | 2021 |
Carboxylesterase Precursor (EST-1) Mediated the Fungicide Jinggangmycin-Suppressed Reproduction of Sogatella furcifera (Hemiptera: Delphacidae).
Topics: Amino Acid Sequence; Animals; Base Sequence; Body Weight; Carbohydrate Metabolism; Carboxylesterase; | 2017 |
Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients.
Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; Drug Therapy, Combination; Female; Humans; Hyper | 2018 |
Intragastric balloon therapy leads to normalization of brain magnetic resonance spectroscopic markers of diabetes in morbidly obese patients.
Topics: Adipose Tissue; Body Mass Index; Body Weight; Brain; Creatine; Diabetes Mellitus, Type 2; Female; Ga | 2018 |
Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model.
Topics: Animals; Body Weight; Disease Models, Animal; Female; Granulosa Cells; Inositol; Light; Male; Mice, | 2019 |
Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Body Weight; Drug Therapy, Combination; Estradiol; Female; Folli | 2019 |
Modified insoluble dietary fibers in okara affect body composition, serum metabolic properties, and fatty acid profiles in mice fed high-fat diets: an NMR investigation.
Topics: Adipose Tissue; Alanine; Animals; Blood Glucose; Body Composition; Body Weight; Cholesterol; Choline | 2019 |
Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS).
Topics: Adult; Blood Glucose; Body Weight; Cohort Studies; Female; Hormones; Humans; Inositol; Polycystic Ov | 2019 |
Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: an observational study.
Topics: Adult; Antioxidants; Body Mass Index; Body Weight; Combined Modality Therapy; Dietary Supplements; F | 2020 |
Voglibose administration regulates body weight and energy intake in high fat-induced obese mice.
Topics: Adiposity; Agouti-Related Protein; Animals; Appetite; Body Weight; Diet, High-Fat; Energy Intake; Ge | 2014 |
Dose-dependent influence of short-term intermittent ethanol intoxication on cerebral neurochemical changes in rats detected by ex vivo proton nuclear magnetic resonance spectroscopy.
Topics: Alanine; Alcoholic Intoxication; Animals; Aspartic Acid; Body Weight; Central Nervous System Depress | 2014 |
Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome.
Topics: Body Weight; C-Reactive Protein; Female; Glucose Tolerance Test; Gonadotropin-Releasing Hormone; Hum | 2014 |
[Effect of sequoyitol on expression of NOX4 and eNOS in aortas of type 2 diabetic rats].
Topics: Animals; Aorta; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2014 |
Jinggangmycin increases fecundity of the brown planthopper, Nilaparvata lugens (Stål) via fatty acid synthase gene expression.
Topics: Animals; Antifungal Agents; Body Weight; Fat Body; Fatty Acid Synthases; Female; Fertility; Gene Exp | 2016 |
Adipose triglyceride lipase (Atgl) mediates the antibiotic jinggangmycin-stimulated reproduction in the brown planthopper, Nilaparvata lugens Stål.
Topics: Animals; Anti-Bacterial Agents; Body Weight; Fat Body; Female; Glycerol; Hemiptera; Inositol; Insect | 2016 |
Beneficial effects of voglibose administration on body weight and lipid metabolism via gastrointestinal bile acid modification.
Topics: Animals; Bile Acids and Salts; Body Weight; Eating; Gastrointestinal Tract; Hypoglycemic Agents; Ino | 2016 |
The effect of combined inositol hexakisphosphate and inositol supplement in streptozotocin-induced type 2 diabetic rats.
Topics: Amylases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 2016 |
Myoinositol ameliorates high-fat diet and streptozotocin-induced diabetes in rats through promoting insulin receptor signaling.
Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diet, Hi | 2017 |
Metabolic response of soy pinitol on lipid-lowering, antioxidant and hepatoprotective action in hamsters fed-high fat and high cholesterol diet.
Topics: Animals; Antioxidants; Body Weight; Cholesterol, Dietary; Cricetinae; Dietary Fats; Eating; Glycine | 2009 |
D-pinitol attenuates the impaired activities of hepatic key enzymes in carbohydrate metabolism of streptozotocin-induced diabetic rats.
Topics: Animals; Body Weight; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Gliclazide; Glucose | 2009 |
Long-term therapeutic effects of voglibose, a potent intestinal alpha-glucosidase inhibitor, in spontaneous diabetic GK rats.
Topics: Alkaline Phosphatase; Animals; Blood Glucose; Blotting, Northern; Blotting, Western; Body Weight; Di | 2003 |
ZINC DEFICIENCY SYNDROME IN THE YOUNG LAMB.
Topics: Animals; Blood Chemical Analysis; Blood Proteins; Body Weight; Deficiency Diseases; Diet; Growth; Hu | 1964 |
[SENILE PONDERAL INVOLUTION. ITS CORRECTION BY A LYSINE-INOSITOL-VITAMIN B12 COMBINATION].
Topics: Body Weight; Corrinoids; Emaciation; Geriatrics; Hematinics; Inositol; Lysine; Vitamin B 12 | 1964 |
THE EFFECT OF COLD EXPOSURE ON PLASMA AND LIVER CHOLESTEROL LEVELS IN RATS FED VARIOUS DIETS.
Topics: Biochemical Phenomena; Biochemistry; Body Weight; Cholesterol; Choline; Choline Deficiency; Cold Tem | 1964 |
STUDIES ON MYO-INOSITOL. I. EFFECT ON THE GROWTH OF RATS.
Topics: Alopecia; Biological Phenomena; Body Weight; Body Weights and Measures; Growth; Inositol; Pharmacolo | 1965 |
D-chiro-Inositol enhances effects of hypothalamic toxin gold-thioglucose.
Topics: Agouti-Related Protein; Analysis of Variance; Animals; Antirheumatic Agents; Aurothioglucose; Body W | 2003 |
The effects of dietary myoinositol on lung tumor development in tobacco smoke-exposed mice.
Topics: Animals; Anticarcinogenic Agents; Body Weight; Carcinogens; Diet; Dose-Response Relationship, Drug; | 2004 |
Evaluation of dietary essentiality of vitamins for Penaeus monodon (Fabricius).
Topics: Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Body Weight; Choline; Crustacea; D | 2004 |
A potent sorbitol dehydrogenase inhibitor exacerbates sympathetic autonomic neuropathy in rats with streptozotocin-induced diabetes.
Topics: Animals; Autonomic Nervous System Diseases; Axons; Blood Glucose; Body Weight; Diabetes Mellitus, Ex | 2005 |
Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice.
Topics: Acetophenones; Animals; Blotting, Western; Body Weight; Cells, Cultured; Disease Progression; Echoca | 2006 |
Inhibition of chronic ulcerative colitis associated adenocarcinoma development in mice by inositol compounds.
Topics: Adenocarcinoma; Animals; Body Weight; Chronic Disease; Colitis, Ulcerative; Colorectal Neoplasms; Fe | 2007 |
Adolescent anorexia nervosa: cross-sectional and follow-up frontal gray matter disturbances detected with proton magnetic resonance spectroscopy.
Topics: Adolescent; Anorexia Nervosa; Aspartic Acid; Body Mass Index; Body Weight; Child; Choline; Combined | 2007 |
D-chiro-inositol found in Cucurbita ficifolia (Cucurbitaceae) fruit extracts plays the hypoglycaemic role in streptozocin-diabetic rats.
Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Cucurbitaceae; Diabetes Mellitus, Experim | 2006 |
IMPA1 is essential for embryonic development and lithium-like pilocarpine sensitivity.
Topics: Animals; Antimanic Agents; Behavior, Animal; Body Weight; Chromatography, Gas; Drinking; Embryonic D | 2008 |
Metabolic effects of a novel silicate inositol complex of the nitric oxide precursor arginine in the obese insulin-resistant JCR:LA-cp rat.
Topics: Animals; Arginine; Blood Glucose; Body Weight; Eating; Female; Inositol; Insulin; Insulin Resistance | 2007 |
Nerve Na+-K+-ATPase, conduction, and myo-inositol in the insulin-deficient BB rat.
Topics: Adenosine Triphosphatases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Diuresis; Inosito | 1984 |
The effect of experimentally induced diabetes on the metabolism of glucose by seminiferous tubules and epididymal spermatozoa from the rat.
Topics: Alloxan; Animals; Blood Glucose; Body Weight; Deoxyglucose; Diabetes Mellitus, Experimental; Epididy | 1984 |
Abnormal sciatic nerve myo-inositol metabolism in the streptozotocin-diabetic rat: effect of insulin treatment.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Inositol; Insulin; Phosphatidy | 1980 |
Impaired rat sciatic nerve sodium-potassium adenosine triphosphatase in acute streptozocin diabetes and its correction by dietary myo-inositol supplementation.
Topics: Acute Disease; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Inositol; Male; | 1983 |
Metabolism of 14C-phytate in rats: effect of low and high dietary calcium intakes.
Topics: Animals; Body Weight; Calcium; Carbon Dioxide; Carbon Radioisotopes; Inositol; Male; Organ Size; Phy | 1980 |
Transport of myo-inositol into endoneurial preparations of sciatic nerve from normal and streptozotocin-diabetic rats.
Topics: Adenosine Triphosphate; Animals; Biological Transport, Active; Body Weight; Diabetes Mellitus, Exper | 1983 |
Myo-inositol-responsive liver lipid accumulation in the rat.
Topics: Animals; Body Weight; Choline; Diet; Fatty Acids; Female; Inositol; Liver; Male; Organ Size; Rats; S | 1980 |
The relative response of hepatic lipids in the rat to graded levels of dietary myo-inositol and other lipotropes.
Topics: Animals; Body Weight; Choline; Choline Deficiency; Dose-Response Relationship, Drug; Drug Synergism; | 1980 |
Effect of myo-inositol supplementation on the development of renal pathological changes in the Cohen diabetic (type 2) rat.
Topics: Animals; Blood Glucose; Body Weight; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 1995 |
Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic N | 1995 |
Effects of vitamin A and inositol on term weights of H-2 congenic mice.
Topics: Animals; Birth Weight; Body Weight; Diet; Embryonic and Fetal Development; Female; Inositol; Mice; M | 1995 |
Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation.
Topics: Aldehyde Reductase; Amino Acid Oxidoreductases; Animals; Arginine; Benzothiazoles; Blood Pressure; B | 1993 |
The effect of choline and myo-inositol on liver and carcass fat levels in aerobically trained rats.
Topics: Adipose Tissue; Aerobiosis; Animals; Body Composition; Body Weight; Choline; Diet; Inositol; Lipids; | 1995 |
Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy.
Topics: Aldehyde Reductase; Animals; Axons; Body Weight; Diabetic Neuropathies; Fructose; Galactitol; Galact | 1994 |
Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Inositol; Male; Motor Neurons; | 1994 |
TCDD decreases brain inositol concentrations in the rat.
Topics: Analysis of Variance; Animals; Body Weight; Brain; Dose-Response Relationship, Drug; Female; Inosito | 1994 |
Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic N | 1993 |
Fatty acid compositions of inositol and choline phospholipids of breast tumours and normal breast tissue.
Topics: Adult; Body Weight; Breast; Breast Neoplasms; Erythrocytes; Fatty Acids; Female; Humans; Inositol; M | 1993 |
Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats.
Topics: Acetanilides; Aldehyde Reductase; Analysis of Variance; Animals; Arginine; Blood Glucose; Body Weigh | 1996 |
Morphophysiologic characterization of peripheral neuropathy in zinc-deficient guinea pigs.
Topics: Animals; Blood Glucose; Body Weight; Brachial Plexus; Carbohydrates; Evoked Potentials, Somatosensor | 1996 |
Glutamine, myo-inositol, and organic brain osmolytes after portocaval anastomosis in the rat: implications for ammonia-induced brain edema.
Topics: Ammonia; Animals; Blood Pressure; Body Water; Body Weight; Brain; Brain Edema; Cerebral Cortex; Glut | 1996 |
Effect of propionyl-L-carnitine on oscillatory potentials in electroretinogram in streptozotocin-diabetic rats.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Body Weight; | 1996 |
Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
Topics: Aldehyde Reductase; Analysis of Variance; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Ex | 1997 |
Oral maternal inositol supplementation does not increase rat conceptus inositol levels.
Topics: Administration, Oral; Animals; Body Weight; Female; Humans; Inositol; Maternal-Fetal Exchange; Pregn | 1997 |
Reduction in fluid secretion by rat testis by drugs that block potassium channels.
Topics: Analysis of Variance; Androgen-Binding Protein; Animals; Anti-Arrhythmia Agents; Body Weight; Inosit | 1998 |
Chemoprevention of tobacco smoke-induced lung tumors in A/J strain mice with dietary myo-inositol and dexamethasone.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Atmosphere Exposure Chambers; Body Weight; Chemopreventi | 1999 |
Inhibition of progressive reduction of islet beta-cell mass in spontaneously diabetic Goto-Kakizaki rats by alpha-glucosidase inhibitor.
Topics: Aging; Animals; Body Weight; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside Hydrolase Inhib | 2000 |
Evaluation of alpha(1)-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Blood Glucose; Blood Pressure; Body Weight; Cre | 2000 |
Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic N | 2000 |
Dose-response study of myo-inositol as an inhibitor of lung tumorigenesis induced in A/J mice by benzo.
Topics: Animals; Anticarcinogenic Agents; Benzo(a)pyrene; Body Weight; Carcinogens; Diet; Dose-Response Rela | 2001 |
Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve.
Topics: Acetylcholine; Animals; Blood Glucose; Blood Vessels; Body Weight; Diabetes Mellitus, Experimental; | 2001 |
The influence of nutritional factors on pulmonary adenomas in mice.
Topics: Adenoma; Animals; Body Weight; Choline; Inositol; Lung Neoplasms; Mice; Mice, Inbred Strains; Niacin | 1977 |
myo-Inositol metabolism in the neonatal and developing rat fed a myo-inositol-free diet.
Topics: 2',3'-Cyclic-Nucleotide Phosphodiesterases; Age Factors; Animals; Animals, Newborn; Body Weight; Bra | 1976 |
Hepatic lipid metabolism in domestic fowl as influenced by dietary cereal.
Topics: Animals; Body Weight; Chickens; Coturnix; Edible Grain; Female; Glycine max; Inositol; Lipid Metabol | 1979 |
The influence of dietary inositol on glyceride composition and synthesis in livers of rats fed different fats.
Topics: Animals; Body Weight; Dietary Fats; Glycerides; Glycerophosphates; Glycine max; Inositol; Lipid Meta | 1976 |
myo-Inositol metabolism during lactation and development in the rat. The prevention of lactation-induced fatty liver by dietary myo-inositol.
Topics: Amniotic Fluid; Animals; Body Weight; Disaccharides; Fatty Liver; Female; Galactose; Inositol; Lacta | 1976 |
Effect of dietary protein on the biosynthesis of inositol in rat testes.
Topics: Animals; Body Weight; Dietary Proteins; Epididymis; Inositol; Male; Organ Size; Protein Deficiency; | 1975 |
Effect of a prostaglandin I2 derivative (iloprost) on peripheral neuropathy of diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Cyclic AMP; Diabetes Mellitus, Experimental; Diabetic Neuropath | 1992 |
Upregulation of D-myo-inositol transport in diabetic rat glomerular cells.
Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Glucose; Inositol; Inositol Phosphates; Insul | 1992 |
Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozo
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic N | 1992 |
Effect of cyclosporine treatment on carnitine and myo-inositol in diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Carnitine; Cyclosporine; Diabetes Mellitus, Experimental; Eatin | 1992 |
Renal sorbitol, myo-inositol and glycerophosphorylcholine in streptozotocin-diabetic rats.
Topics: Animals; Blood Glucose; Blood Proteins; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Di | 1992 |
Amelioration of nerve Na(+)-K(+)-ATPase activity independently of myo-inositol level by PGE1 analogue OP-1206.alpha-CD in streptozocin-induced diabetic rats.
Topics: Alprostadil; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Inositol; Male; M | 1991 |
Diminished specific activity of cytosolic protein kinase C in sciatic nerve of streptozocin-induced diabetic rats and its correction by dietary myo-inositol.
Topics: Administration, Oral; Animals; Blood Glucose; Blotting, Western; Body Weight; Cytosol; Diabetes Mell | 1991 |
Effect of short- and long-term diabetes on carnitine and myo-inositol in rats.
Topics: Acute Disease; Animals; Blood Glucose; Body Weight; Carnitine; Chronic Disease; Diabetes Mellitus, E | 1991 |
Beta adrenergic receptor alterations in diabetic rat prostate: effects of insulin and dietary myoinositol.
Topics: Adrenergic beta-Antagonists; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; D | 1991 |
Nerve conduction velocity and axonal transport of 6-phosphofructokinase activity in galactose-fed rats.
Topics: Aldehyde Reductase; Animals; Axonal Transport; Blood Glucose; Body Weight; Carbohydrate Metabolism; | 1991 |
Effects of insulin and myo-inositol on embryo growth and development during early organogenesis in streptozocin-induced diabetic rats.
Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Diet; Embryonic and Fetal Development; Female | 1991 |
Adenosine triphosphatase activity in sciatic nerve tissue of streptozocin-induced diabetic rats with and without high dietary sucrose: effect of aldose reductase inhibitors.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dietary Ca | 1991 |
Aldose reductase activity and myo-inositol levels in sciatic nerve and dorsal root ganglia of the diabetic mutant mouse [C57/BL/Ks (db/db)].
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Ganglia, S | 1991 |
The significance of nerve sugar levels for the peripheral nerve impairment of spontaneously diabetic GK (Goto-Kakizaki) rats.
Topics: Aging; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Fructose; Glucose; Inos | 1990 |
A defect in sodium-dependent amino acid uptake in diabetic rabbit peripheral nerve. Correction by an aldose reductase inhibitor or myo-inositol administration.
Topics: Amino Acids; Aminoisobutyric Acids; Animals; Biological Transport; Blood Glucose; Body Weight; Diabe | 1990 |
Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus.
Topics: Age Factors; Animals; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dogs; | 1990 |
Reversal of deficits in axonal transport and nerve conduction velocity by treatment of streptozotocin-diabetic rats with myo-inositol.
Topics: Administration, Oral; Animals; Axonal Transport; Blood Glucose; Body Weight; Diabetes Mellitus, Expe | 1985 |
Studies on peripheral nerve and lens in long-term experimental diabetes: effects of the aldose reductase inhibitor statil.
Topics: Aldehyde Reductase; Animals; Axonal Transport; Body Weight; Carbohydrates; Choline O-Acetyltransfera | 1988 |
Effects of sorbinil treatment in rats with chronic streptozotocin-diabetes; changes in lens and in substance P and catecholamines in the iris.
Topics: Animals; Blood Glucose; Body Weight; Catecholamines; Diabetes Mellitus, Experimental; Epinephrine; I | 1989 |
Substance P levels in peripheral nerve, skin, atrial myocardium and gastrointestinal tract of rats with long-term diabetes mellitus. Effects of aldose reductase inhibition.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Digestive | 1989 |
Effects of streptozotocin-induced hyperglycemia on agonist-stimulated phosphatidylinositol turnover in rat aorta.
Topics: Animals; Aorta, Thoracic; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Hyperglycemia | 1989 |
Inositol and inositol hexaphosphate suppress cell proliferation and tumor formation in CD-1 mice.
Topics: 1,2-Dimethylhydrazine; Animals; Body Weight; Carcinogens; Cell Division; Dimethylhydrazines; Inosito | 1989 |
Inositol and choline levels in the diet and neutral lipid hepatic content of lactating rat.
Topics: Animals; Body Weight; Choline; Dietary Proteins; Female; Inositol; Lactation; Lipoproteins; Liver; O | 1989 |
Inositol affects the intracellular turnover of pulmonary surfactant phospholipids in the rat.
Topics: Animals; Body Weight; Diarrhea; Female; Inclusion Bodies; Inositol; Lung; Lung Compliance; Metabolic | 1985 |
Decreased myo-inositol content and Na+-K+-ATPase activity in superior cervical ganglion of STZ-diabetic rat and prevention by aldose reductase inhibition.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Ganglia, S | 1986 |
The effects of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat.
Topics: Age Factors; Aldehyde Reductase; Animals; Axons; Blood Glucose; Body Weight; Diabetes Mellitus, Expe | 1986 |
Prevention of neural myoinositol depletion in diabetic rats by aldose reductase inhibition with tolrestat.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Glucose; I | 1986 |
Glucosylceramide and the level of the glucosidase-stimulating proteins.
Topics: Animals; beta-Glucosidase; Body Weight; Brain; Cell Membrane; Cerebrosides; Cytosol; Glucosidases; G | 1986 |
Inositol and glucocorticoid in the development of lung stability in male and female rabbit fetuses.
Topics: Animals; Betamethasone; Body Weight; Female; Fetal Organ Maturity; Glucose; Inositol; Lung; Pregnanc | 1988 |
Methylcobalamin improves nerve conduction in streptozotocin-diabetic rats without affecting sorbitol and myo-inositol contents of sciatic nerve.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Inositol; Male; Neural Conduct | 1988 |
Diabetes affects sorbitol and myo-inositol levels of neuroectodermal tissue during embryogenesis in rat.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Body Weight; Creatine; Diabetes Mellitus, Ex | 1988 |
Does galactose feeding provide a valid model of consequences of exaggerated polyol-pathway flux in peripheral nerve in experimental diabetes?
Topics: Animals; Blood Glucose; Body Water; Body Weight; Diabetes Mellitus, Experimental; Galactosemias; Ino | 1987 |
Lipotropic activity of inositol and chlortetracycline alone and in various combinations of choline, vitamin B 12 and folic acid. Activity of three liver extracts with assays for these substances.
Topics: Animals; Body Weight; Cattle; Chlortetracycline; Choline; Dietary Fats; Drug Combinations; Fatty Liv | 1971 |
Lipotropic factors for beef cattle fed high-concentrate diets.
Topics: Animal Feed; Animals; Body Weight; Cattle; Choline; Diet; Female; Folic Acid; Injections, Intraperit | 1974 |
Inositol requirement of the gerbil.
Topics: Animal Nutritional Physiological Phenomena; Animals; Body Weight; Cholesterol, Dietary; Cocos; Defic | 1974 |
Effect of selenium and lipotropic factors on liver fat accumulation in laying hens.
Topics: Animal Feed; Animals; Body Weight; Chickens; Choline; Dietary Fats; Eggs; Female; Glycine max; Inosi | 1974 |
Hematologic and biochemical effects of simulated high altitude on the Japanese quail.
Topics: Altitude; Animals; Blood Glucose; Blood Volume; Body Weight; Carbohydrate Metabolism; Cardiomegaly; | 1974 |
Effect of supplemental phytase on the utilization of phytate phosphorus by chicks.
Topics: 6-Phytase; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Aspergillus; Body Weigh | 1971 |
Influence of neonatal undernutrition on the lipid composition of cerebral cortex and cerebellum of the rat.
Topics: Animals; Animals, Newborn; Body Weight; Brain; Brain Chemistry; Cerebellum; Cerebral Cortex; Cerebro | 1972 |
The lack of effect of dietary inositol supplementation on egg production and liver lipid metabolism in the laying hen.
Topics: Animal Feed; Animals; Body Weight; Chickens; Diet; Eggs; Female; Inositol; Lipid Metabolism; Lipids; | 1972 |
Effect of diet on fatty liver-hemorrhagic syndrome incidence in laying chickens.
Topics: Animals; Body Weight; Chickens; Choline; Cobalt; Diet; Fatty Liver; Female; Hemorrhage; Inositol; Li | 1972 |
Effects of dietary calcium and phosphorus on growth, food conversion, bone ash and hematocrit levels of catfish.
Topics: Animal Nutritional Physiological Phenomena; Animals; Body Weight; Bone and Bones; Calcium, Dietary; | 1973 |
Effects of inositol, diphenylhydantoin and phenobarbital on HEOD storage in rat adipose tissue.
Topics: Adipose Tissue; Aminopyrine N-Demethylase; Animals; Body Weight; Dieldrin; Inositol; Male; Microsome | 1973 |
Factors influencing the quality of abdominal fat in broilers. 1. Rearing temperature, sex, age or weight, and dietary choline chloride and inositol supplementation.
Topics: Abdomen; Adipose Tissue; Age Factors; Animal Feed; Animals; Body Weight; Choline; Female; Inositol; | 1974 |
Studies on myoinositol. IX. Morphological examinaiton of the effect of massive doses of myoinositol on the liver and kidney of rat.
Topics: Animals; Body Weight; Female; Inositol; Kidney; Liver; Male; Rats | 1974 |
The effects of local heating of the testis on the flow and composition of rete testis fluid in the rat, with some observations on the effects of age and unilateral castration.
Topics: Age Factors; Animals; Body Weight; Castration; Glycine; Hot Temperature; Inositol; Male; Organ Size; | 1972 |
Phosphorus metabolism in ponies fed varying levels of phosphorus.
Topics: Animals; Blood; Body Weight; Calcium; Calcium, Dietary; Castration; Feces; Homeostasis; Horses; Inos | 1971 |
Studies on myoinositol. VI. Effect of myoinositol on plasma lipoprotein metabolism of rats suffering from fatty liver.
Topics: Acetates; Animals; Body Weight; Carbon Isotopes; Cholesterol; Fatty Liver; Inositol; Leucine; Lipopr | 1970 |
The lack of effect of dietary inositol in depressing liver lipids in the hen.
Topics: Animal Feed; Animals; Body Weight; Chickens; Eggs; Female; Inositol; Lipid Metabolism; Lipids; Liver | 1970 |
Observations on the synthesis, chemical hydrolysis in vitro and toxicity of a new ester of nicotinic acid: the mesoinosito pentanicotinate.
Topics: Abnormalities, Drug-Induced; Animals; Animals, Newborn; Blood; Body Weight; Chemistry, Pharmaceutica | 1970 |
Studies on myoinositol. II. Possible role of dietary myoinositol on the growth promotion of young rats.
Topics: Animals; Animals, Newborn; Body Weight; Choline; Dietary Proteins; Growth; In Vitro Techniques; Inos | 1966 |